As far as the declining percentage of sales of research spending, there is a published document by the PMPRB that lays that out very clearly, and over the last nine years the trend has been decreasing.
Regarding Alzheimer's, certainly it appears to be an unmet need in the market. We're clearly in favour of innovation. We believe the intellectual property regime in Canada is sufficient to allow brand-name pharmaceutical companies to have an appropriate return on their investments, especially in new research with product categories like Alzheimer's.
It's not like the generic companies are against innovation. That's what keeps the pharmaceutical business going: new products that create innovation; markets grow and then their patent life expires; and then generics come out with cost-saving alternatives. It's a cycle that's been going on for years, and we think it's a very productive cycle.